The challenge of managing patients with polyarteritis nodosa

Current Opinion in Rheumatology

Volumn 19, Issue 1, 2007, Pages 33-38

  Segelmark, Mårten ^a,b   Selga, Daina ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Classification; Hepatitis; Microscopic polyangiitis; Polyarteritis nodosa; Vasculitis

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY;

ALGORITHM; CLINICAL FEATURE; CONSENSUS; DISEASE CLASSIFICATION; DISEASE COURSE; HEPATITIS; HISTORY OF MEDICINE; HUMAN; POLYARTERITIS NODOSA; PRIORITY JOURNAL; REVIEW; SKIN DISEASE;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; HEPATITIS B; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; POLYARTERITIS NODOSA; SOCIETIES, MEDICAL; UNITED STATES;

EID: 33845372641     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328011cb6f     Document Type: Review

References (46)

1. Oomura M, Yamawaki T, Naritomi H, et al. Polyarteritis nodosa in association with subarachnoid hemorrhage. Intern Med 2006; 45:655-658.
2. Karademir K, Senkul T, Atasoyu E, et al. Ulcerative necrosis of the glans penis resulting from polyarteritis nodosa. J Clin Rheumatol 2005; 11:167-169.
3. Herve F, Heron F, Levesque H, Marie I. Ascites as the first manifestation of polyarteritis nodosa. Scand J Gastroenterol 2006; 41:493-495.
4. Emad Y, Basaffar S, Ragab Y, et al. A case of polyarteritis nodosa complicated by left central retinal artery occlusion, ischemic optic neuropathy, and retinal vasculitis. Clin Rheumatol 2006; Epub ahead of print.
5. Kussmaul A, Maier R. Uber eine bisher nicht beschreibene eigenthümliche Arterienerkankung (Periarteriitis nodosa), die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellähmung einhergeht. Dtsch Arch Klin Med 1866; 1:484-517.
6. Wegener F. Über generalisierte septische Gefäbetaerkrankungen. Verh Dtsch Ges Pathol 1936; 29:202-210.
7. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27:277-301.
8. Davson J, Ball J, Platt R. The kidney in periarteritis nodosa. QJM 1948; 17:175-205.
9. Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33:1088-1093.
10. Trepo C, Thivolet J. Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang 1970; 19:410-411.
11. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006; 65:936-941. A new updated classification scheme splitting the old term PAN into classical PAN, cutaneous PAN, MPA and HBV-related PAN.
12. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum 1994; 37:187-192.
13. Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM 2005; 98:97-111.
14. Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75:17-28.
15. Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666-675.
16. Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005; 84:323-330.
17. Guillevin L, Lhote F, Amouroux J, et al. Antineutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: indications for the classification of vasculitides of the polyarteritis Nodosa Group. Br J Rheumatol 1996; 35:958-964.
18. Levine SM, Hellmann DB, Stone JH. Gastrointestinal involvement in polyarteritis nodosa (1986-2000) presentation and outcomes in 24 patients. Am J Med 2002; 112:386-391.
19. Pagnoux C, Mahr A, Cohen P, Guillevin L. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 2005; 84:115-128.
20. Lhote F, Cohen P, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Lupus 1998; 7:238-258.
21. Feinstein J, Arroyo R. Successful treatment of childhood onset refractory polyarteritis nodosa with tumor necrosis factor alpha blockade. J Clin Rheumatol 2005; 11:219-222.
22. Asano Y, Ihn H, Maekawa T, et al. High-dose intravenous immunoglobulin infusion in polyarteritis nodosa: report on one case and review of the literature. Clin Rheumatol 2006; 25:396-398.
23. Wu K, Throssell D. A new treatment for polyarteritis nodosa. Nephrol Dial Transplant 2006; 21:1710-1712.
24. Bae YD, Choi HJ, Lee JC, et al. Clinical features of polyarteritis nodosa in Korea. J Korean Med Sci 2006; 21:591-595. Provides interesting data of PAN from an Asian country, most other PAN cohorts in the literature stem from Caucasian populations.
25. Kamali S, Inanc M, Gul A, et al. Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients. Rheumatol Int 2005; 26:16-20.
26. el-Reshaid K, Kapoor MM, el-Reshaid W, et al. The spectrum of renal disease associated with microscopic polyangiitis and classic polyarteritis nodosa in Kuwait. Nephrol Dial Transplant 1997; 12:1874-1882.
27. Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum 2004; 51:92-99.
28. Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84:313-322. The most significant contribution to the PAN field in recent years. Provides an excellent overview of most clinical aspects of HBV-related PAN as well as solid evidence-based treatment suggestions.
29. Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun 2001; 16:269-274.
30. Farrell GC, Teoh NC. Management of chronic hepatitis B virus infection: a new era of disease control. Intern Med J 2006; 36:100-113.
31. Ramos-Casals M, Jara LJ, Medina F, et al. Systemic autoimmune diseases coexisting with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. J Intern Med 2005; 257:549-557.
32. Canada R, Chaudry S, Gaber L, et al. Polyarteritis nodosa and cryoglobulinemic glomerulonephritis related to chronic hepatitis C. Am J Med Sci 2006; 331:329-333.
33. Cacoub P, Maisonobe T, Thibault V, et al. Systemic vasculitis in patients with hepatitis C. J Rheumatol 2001; 28:109-118.
34. Fathalla BM, Miller L, Brady S, Schaller JG. Cutaneous polyarteritis nodosa in children. J Am Acad Dermatol 2005; 53:724-728.
35. Kamimura T, Hatakeyama M, Torigoe K, et al. Muscular polyarteritis nodosa as a cause of fever of undetermined origin: a case report and review of the literature. Rheumatol Int 2005; 25:394-397.
36. MacLaren K, Gillespie J, Shrestha S, et al. Primary angiitis of the central nervous system: emerging variants. QJM 2005; 98:643-654.
37. Watts RA, Gonzalez-Gay MA, Lane SE, et al. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis 2001; 60:170-172.
38. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum 2005; 53:93-99.
39. Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42:421-430.
40. Pavone L, Grasselli C, Chierici E, et al. Outcome and prognostic factors during the course of primary small-vessel vasculitides. J Rheumatol 2006; 33:1299-1306.
41. Westman KW, Selga D, Isberg PE, et al. High proteinase 3-antineutrophil cytoplasmic antibody (ANCA) level measured by the capture enzyme-linked immunosorbent assay method is associated with decreased patient survival in ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 2003; 14:2926-2933.
42. Selga D, Mohammad A, Sturfelt G, Segelmark M. Polyarteritis nodosa when applying the Chapel Hill nomenclature - a descriptive study on ten patients. Rheumatology (Oxford) 2006; 45:1276-1281. The first attempt to our knowledge to describe classical PAN when strictly applying the CHCC nomenclature.
43. Gibson A, Stamp LK, Chapman PT, O'Donnell JL. The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology (Oxford) 2006; 45:624-628.
44. Weidner S, Geuss S, Hafezi-Rachti S, et al. ANCA-associated vasculitis with renal involvement: an outcome analysis. Nephrol Dial Transplant 2004; 19:1403-1411.
45. Hauer HA, Bajema IM, Van Houwelingen HC, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 2002; 62:1732-1742.
46. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2006; doi:10.1136/ard.2006.054593. An international collaboration effort in order to provide a practical guideline on how to use CHCC nomenclature and ACR criteria for epidemiological studies. The classification algorithm proposed can easily be adopted also in prospective studies and clinical trials.